Explore our blogs on various markets

Several large language models (LLMs) are already being used or evaluated by pharmaceutical companies and health tech teams. From accelerating drug discovery to streamlining regulatory submissions and enhancing patient education, LLMs are redefining how life sciences teams work with data, documents, and decisions.. Unlike traditional AI systems, LLMs can read, understand, and generate natural language at scale, making them ideal for navigating the complexity of biomedical literature, clinical protocols, compliance guidelines, and real-world evidence....

Generative AI is helping doctors and scientists design personalized medicine faster and more accurately. These AI tools use medical, genetic, and clinical data to create treatment plans, drugs, and predictions that match an individual’s unique biology.. Researchers and biotech companies are now using generative AI (GenAI) models to improve patient care...

AI and ML imaging tools are now central to drug discovery. These systems process cell images to detect drug effects, predict safety, and optimize compounds. In this news article, you will find how AI and ML-based imaging are reshaping drug discovery in 2025....

Regulatory impact assessment (RIA) is an essential step for ensuring pharmaceutical product compliance, quality, and safety whenever changes occur in products or their manufacturing processes. However, this process has traditionally been complex and time-consuming, with risks of delaying product availability and increasing regulatory workload.. Today, Generative AI (GenAI) is rapidly changing this landscape, presenting new opportunities for efficiency and accuracy across global pharma operations....

It processes over one thousand interactions per week on cloud infrastructure, making high-precision ligand binding calculations available through a user-friendly interface.. How XFEP Works with High‑Precision Physics and AI‑Driven Modeling. Physics‑Driven Free Energy Perturbation Enables Accurate Binding Predictions...